Paliperidone: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Paliperidone. Educational only — not medical advice.
Labeled uses
INVEGA HAFYERA, an every-six-month injection, is indicated for the treatment of schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA SUSTENNA) for at least four months, or An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA TRINZA) for at least one three-month cycle.
Source: FDA labeling via NIH DailyMed (set 6cd61892…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.